Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 302, Issue 2, 2002, Pages 742-750

  Veau, Celine ^a,b,c   Faivre, Laurence ^a,b,c   Tardivel, Sylviane ^a,b,c   Soursac, Mireille ^a,b,c   Banide, Helene ^a,b,c   Lacour, Bernard ^a,b,c   Farinotti, Robert ^a,b,c  

^a Unité Propre de Recherche de l'Enseignement Supérieur 2706   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DIGOXIN; GLYCOPROTEIN P; RECOMBINANT INTERLEUKIN 2; RHODAMINE 123; SAQUINAVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; FIRST PASS EFFECT; INTESTINE ABSORPTION; INTESTINE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL AVAILABILITY; DIGOXIN; DNA PRIMERS; GENE EXPRESSION REGULATION; INTERLEUKIN-2; INTESTINAL ABSORPTION; KINETICS; MALE; MICE; MICE, INBRED STRAINS; P-GLYCOPROTEIN; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHODAMINE 123;

EID: 0036073339     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.302.2.742     Document Type: Article

References (39)

1. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
2. Mechanisms of interleukin-2-induced depression of hepatic cytochrome P-450 in mice
3. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line caco-2
4. Genetic analysis of the phenobarbital regulation of the cytochrome P-450 2b-9 and aldehyde dehydrogenase type 2 mRNAs in mouse liver
5. Involvement of P-glycoprotein in the transmembrane transport of interleukin 2 (IL-2), IL-4 and interferon-γ in normal human T lymphocytes
6. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4
7. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampicin
8. Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system
9. P-glycoproteinmediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P-450 3A4
10. Functional polymorphism of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
11. P-glycoprotein limits oral bioavailability, brain and fetal penetration of saquinavir even with high doses of ritonavir
12. Physiological based pharmacokinetics of digoxin in mdr1a knockout mice
13. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
14. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
15. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype
16. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: Potential for a role in cancer chemotherapy
17. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors
18. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression
19. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein
20. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression
21. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection
22. Tissue and cell distribution of the multidrug resistance associated protein (MRP) in mouse intestine and kidney
23. Ritonavir induces P-glycoprotein expression, multidrug-resistance-associated protein (MRP1) expression and drug transported-mediated activity in a human intestinal cell line
24. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus
25. Interaction of itraconazole and digoxin
26. Effects of ketoconazole on digoxin absorption and disposition in rat
27. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
28. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
29. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells
30. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia
31. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier
32. Cellular localization of the multi-drug-resistance gene product P-glycoprotein in normal human tissues
33. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes
34. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines
35. Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion
36. Active secretion and enterocystic drug metabolism barriers to drug absorption
37. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
38. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats and in cultured cells
39. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P450 3A-related compounds